ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ab Science

Ab Science (AB)

0.785
-0.005
(-0.63%)
Closed December 03 11:30AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.785
Bid
0.78
Ask
0.801
Volume
23,024
0.776 Day's Range 0.80
0.77 52 Week Range 4.465
Market Cap
Previous Close
0.79
Open
0.79
Last Trade
3
@
0.785
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
36,339
Shares Outstanding
52,071,069
Dividend Yield
-
PE Ratio
-3.39
Earnings Per Share (EPS)
-0.23
Revenue
970k
Net Profit
-11.99M

About Ab Science

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Paris, Paris, Fra
Founded
-
Ab Science is listed in the Pharmaceutical Preparations sector of the Euronext with ticker AB. The last closing price for Ab Science was 0.79 €. Over the last year, Ab Science shares have traded in a share price range of 0.77 € to 4.465 €.

Ab Science currently has 52,071,069 shares outstanding. The market capitalization of Ab Science is 41.14 € million. Ab Science has a price to earnings ratio (PE ratio) of -3.39.

AB Latest News

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN...

AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS...

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S...

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL...

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE...

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024...

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science          COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE...

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities          PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS...

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by...

AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros

AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REALISE LE REGLEMENT LIVRAISON...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0151.948051948050.770.8430.77262220.80263709DE
4-0.225-22.27722772281.011.020.77404950.86323457DE
12-0.205-20.70707070710.991.0620.77363390.94574428DE
26-0.315-28.63636363641.11.70.77655421.14558508DE
52-1.915-70.92592592592.74.4650.77986162.19130691DE
156-11.275-93.490878938612.0613.340.77952704.63110648DE
260-4.795-85.93189964165.5821.750.771455618.561332DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALCYBCybergun
0.0002 €
(100.00%)
10.06M
ALVETEGEIRO Pharma
0.124 €
(58.97%)
481.8k
ALDVAlliance Developpement Capital Siic
0.074 €
(32.14%)
6k
MLSRPSpeed Rabbit Pizza
8.20 €
(30.16%)
19
MLSEQSequa Petroleum NV
0.011 €
(29.41%)
12k
MLCOTCoretech 5
0.01 €
(-41.18%)
200
ATOAtos SE
0.495 €
(-32.65%)
17.92M
AFMEAffluent Medical
1.20 €
(-21.05%)
21.92k
ALBIOBiosynex
2.095 €
(-18.32%)
26.9k
TRACTTeract SA
1.03 €
(-15.23%)
76.91k
BCPBanco Comercial Portugues SA
0.4457 €
(2.20%)
44.64M
ALNEVNeovacs
0.0003 €
(0.00%)
33.59M
ATOAtos SE
0.495 €
(-32.65%)
17.92M
ALCYBCybergun
0.0002 €
(100.00%)
10.06M
ORAOrange.
9.706 €
(-2.99%)
9.65M

Discussion

View Full Feed
Stock_Barber Stock_Barber 3 minutes ago
It certainly looks as if Linda led people here astray.
And Poo cannot articulate any excuse for it.
Indeed! There really is no excuse for repeatedly claiming that they would file for OTCQB LAST year, but not doing so!

However, the false "promise" led to gamblers and P&D
DBMM
CAN11 CAN11 3 minutes ago
Thud. That is the sound of their last BIG announcement hitting the ground just like the previous 100 BIG announcements. No believers.
PSRU
i_like_bb_stock i_like_bb_stock 3 minutes ago
YYAI grabbed some 1.45 ready to bounce the ole CNXA
YYAI
Lone Clone Lone Clone 3 minutes ago
Pan American Silver Completes the Sale of La Arena

https://www.businesswire.com/news/home/20241203648739/en/

December 03, 2024 05:00 AM Eastern Standard Time

VANCOUVER, British Columbia--(BUSINESS WIRE)--Pan American Silver Corp. (NYSE: PAAS) (TSX: PAAS)
getReady getReady 3 minutes ago
If this has what it takes to make it to a nickel we will see dollars not long after.
RDAR
Trooperstocks Trooperstocks 4 minutes ago
$CBDW Redefining Investor Relations "As technology reshapes business communication, 1606 Corp (CBDW) is redefining investor relations and customer engagement with its innovative AI-powered chatbot platform." https://cbdw.ai/
#AI #InvestorRelations #CBDW #NaturalLanguageProcessing #PredictiveA
CBDW
north40000 north40000 4 minutes ago
Eh?? You must mean Eddingpharm knew not on a list for 2024.
AMRN
Doubledown75 Doubledown75 4 minutes ago
OTC holding up the show?
Typical
https://x.com/dave_oswald_ceo/status/1863992799718187039?s=46


BLEG
joe botts joe botts 5 minutes ago
Billions
Zorch305 Zorch305 5 minutes ago
What you got one share left from last RS? Buy low
BB
burner67 burner67 5 minutes ago
100%
BEGI
LowFloatLopes LowFloatLopes 6 minutes ago
Nice I slapped 10k to help the cause :) 
AZRH
Bubae Bubae 7 minutes ago
What those loading up on 8s now don't understand is that the dilution hasn't even started yet. The 60.2 million shares that have been issued is for fees and expenses and was likely issued right after the outstanding share count update of November 15th. Now they need a 20 day closing low price to set
BEGI
MartinLutherKing MartinLutherKing 7 minutes ago
Big Buy pressure with cancer breakthrough with microscopic float
RNAZ
PinkPennies PinkPennies 8 minutes ago
took some on that dip as well .. will hold to see what happens

EDBL .166 on watch .. no particular reason other than low float bottom play ..
EDBL
ORCA ORCA 9 minutes ago
JNSH.0024.IN THE 2025 the Penny market will go Ballistic.IN The beggining of 2025 a ton of money will be coming in the stock market.Enormous amount of money will be made.The volumes will come here for sure:)))JNSH should be trading in the .01 minimum.THE TIME WILL COME.THERE IS NO DOUBT ABOUT IT.
JNSH
elks elks 9 minutes ago
moving money around probably will add again today AZRH !!!!!!
AZRH
goopguy77 goopguy77 9 minutes ago
I do not remember my original account details. Does that mean I will be stuck in here forever?
linkvest linkvest 9 minutes ago
I'd be happy with just a nickel LMAO...
RDAR
MartinLutherKing MartinLutherKing 9 minutes ago
Get in if you believe get out if you don’t Cancer world wide nobel prize breakthrough
RNAZ
Rambo Rell Rambo Rell 9 minutes ago
$ILLR Sean Kim’s track record of driving user engagement and profitability makes him the perfect fit for Triller’s growth ambitions. Big innovations and business ventures are on the horizon for $ILLR. 🚀 #SeanKim #TrillerSuccess
ILLR
art2426 art2426 9 minutes ago
>>>"Dr. Koneru is Director of Program Management for a contract manufacturing organization
BIEL
sumbuysumsell sumbuysumsell 9 minutes ago
.
AVXL
sumbuysumsell sumbuysumsell 9 minutes ago
a bit tongue in cheek but doesn't amazon only sell products made in the peoples republic of china?
AVXL